Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: Role of cAMP-dependent protein kinase A signaling pathway

Cancer Research

Volumn 65, Issue 6, 2005, Pages 2303-2313

  Huang, Wen Chin ^a   Xie, Zhihui ^a   Konaka, Hiroyuki ^a   Sodek, Jaro ^b   Zhau, Haiyen E ^a   Chung, Leland W K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUCLADESINE; CRE RECOMBINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FORSKOLIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; OSTEOCALCIN; SIALOPROTEIN;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE DELETION; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION;

BASE SEQUENCE; CELL LINE, TUMOR; CREB-BINDING PROTEIN; CULTURE MEDIA, CONDITIONED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; OSTEOCALCIN; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RNA, MESSENGER; SIALOGLYCOPROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS;

EID: 16844364795     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3448     Document Type: Article

References (59)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Martinez J, Silva S, Santibanez JF. Prostate-derived soluble factors block osteoblast differentiation in culture. J Cell Biochem 1996;61:18-25.
3. Lang SH, Clarke NW, George NJ, Allen TD, Testa NG. Interaction of prostate epithelial cells from benign and malignant tumor tissue with bone-marrow stroma. Prostate 1998;34:203-13.
4. Chung LW. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer 2003;97:772-8.
5. Curatolo C, Ludovico GM, Correale M, et al. Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase. Eur Urol 1992;21Suppl 1:105-7.
6. Waltregny D, Bellahcene A, Van Riet I, et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 1998;90:1000-8.
7. Carlinfante G, Vassilioul D, Svensson O, Wendel M, Heinegard D, Andersson G. Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis 2003;20:437-44.
8. Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001;61:6012-9.
9. Yeung F, Law WK, Yeh CH, et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 2002;277:2468-76.
10. Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994;145:610-23.
11. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39:246-61.
12. Price PA, Otsuka AA, Poser JW, Kristaponis J, Raman N. Characterization of a γ-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci U S A 1976;73:1447-51.
13. Boskey AL, Gadaleta S, Gundberg C, Doty SB, Ducy P, Karsenty G. Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone 1998;23:187-96.
14. 2+-binding protein of bone matrix. Haemostasis 1986;16:258-72.
15. Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996;382:448-52.
16. Ganss B, Kim RH, Sodek J. Bone sialoprotein. Crit Rev Oral Biol Med 1999;10:79-98.
17. Hunter GK, Goldberg HA. Nucleation of hydroxyapatite by bone sialoprotein. Proc Natl Acad Sci U S A 1993;90:8562-5.
18. 3 potentiate bone resorption. J Biol Chem 1993;268:9901-7.
19. Mintz KP, Grzesik WJ, Midura RJ, Robey PG, Termine JD, Fisher LW. Purification and fragmentation of nondenatured bone sialoprotein: evidence for a cryptic, RGD-resistant cell attachment domain. J Bone Miner Res 1993;8:985-95.
20. Zhang JH, Tang J, Wang J, et al. Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncol 2003;23:1043-8.
21. Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 2000;275:16666-72.
22. Roach HI. Why does bone matrix contain non-collagenous proteins? The possible roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralisation and resorption. Cell Biol Int 1994;18:617-28.
23. Stein GS, Lian JB, Owen TA. Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J 1990;4:3111-23.
24. Kondo H, Ohyama T, Ohya K, Kasugai S. Temporal changes of mRNA expression of matrix proteins and parathyroid hormone and parathyroid hormone-related protein (PTH/PTHrP) receptor in bone development. J Bone Miner Res 1997;12:2089-97.
25. Richards JS. New signaling pathways for hormones and cyclic adenosine 3′,5′-monophosphate action in endocrine cells. Mol Endocrinol 2001;15:209-18.
26. Liu AY. Differentiation-specific increase of cAMP-dependent protein kinase in the 3T3-L1 cells. J Biol Chem 1982;257:298-306.
27. Schwartz DA, Rubin CS. Regulation of cAMP-dependent protein kinase subunit levels in Friend erythroleukemic cells. Effects of differentiation and treatment with 8-Br-cAMP and methylisobutyl xanthine. J Biol Chem 1983;258:777-84.
28. Li M, West JW, Numann R, Murphy BJ, Scheuer T, Catterall WA. Convergent regulation of sodium channels by protein kinase C and cAMP-dependent protein kinase. Science 1993;261:1439-42.
29. Roesler WJ, Vandenbark GR, Hanson RW. Cyclic AMP and the induction of eukaryotic gene transcription. J Biol Chem 1988;263:9063-6.
30. Boguslawski G, Hale LV, Yu XP, et al. Activation of osteocalcin transcription involves interaction of protein kinase A- and protein kinase C-dependent pathways. J Biol Chem 2000;275:999-1006.
31. Servillo G, Della Fazia MA, Sassone-Corsi P. Coupling cAMP signaling to transcription in the liver: pivotal role of CREB and CREM. Exp Cell Res 2002;275:143-54.
32. Sassone-Corsi P. Coupling gene expression to cAMP signalling: role of CREB and CREM. Int J Biochem Cell Biol 1998;30:27-38.
33. Yang R, Gerstenfeld LC. Signal transduction pathways mediating parathyroid hormone stimulation of bone sialoprotein gene expression in osteoblasts. J Biol Chem 1996;271:29839-46.
34. 2 stimulates bone sialoprotein (BSP) expression through cAMP and fibroblast growth factor 2 response elements in the proximal promoter of the rat BSP gene. J Biol Chem 2003;278:28659-67.
35. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51:3753-61.
36. Kiyoshima T, Yamauchi M, Wong C, Jheon A, Ganss B, Sodek J. An L1 element disrupts human bone sialoprotein promoter: lack of tissue-specific regulation by distalless5 (Dlx5) and runt homeodomain protein2 (Runx2)/core binding factor a1 (Cbfa1) elements. Gene 2002;299:205-17.
37. Ausubel FM, Brent R, Kingston RE, et al. Current protocols in molecular biology. New York: Greene Pub. Associates and Wiley-Interscience; 1999. p. 12-1-1-12-2-10.
38. 3 on its receptor mRNA levels and osteocalcin synthesis in human osteosarcoma cells. Biochim Biophys Acta 1990;1048:30-7.
39. Chijiwa T, Mishima A, Hagiwara M, et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino) ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 1990;265:5267-72.
40. Chung LW, Hsieh CL, Law A, et al. New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions. Urology 2003;62:44-54.
41. Thalmann GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999;5:2271-7.
42. Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 1999;59:4453-7.
43. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000;6:1140-9.
44. Yeung F, Chung LW. Molecular basis of co-targeting prostate tumor and stroma. J Cell Biochem Suppl 2002;38:65-72.
45. Lin DL, Tarnowski CP, Zhang J, et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001;47:212-21.
46. Ou YC, Chen JT, Yang CR, Ko JL, Hsieh YS, Kao C. Expression of osteocalcin in prostate cancer before and after hormonal therapy. Anticancer Res 2003;23:3807-11.
47. Huang WC, Zhau HE, Chung LW. Invasive prostate cancer cells secret soluble protein factors that upregulate osteocalcin (OC) promoter activity: implication to stroma desmoplastic response and cancer metastasis. J Urol 2003;169:154-4; abstract 597.
48. Xiao G, Jiang D, Gopalakrishnan R, Franceschi RT. Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2. J Biol Chem 2002;277:36181-7.
49. Kim HJ, Kim JH, Bae SC, Choi JY, Ryoo HM. The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem 2003;278:319-26.
50. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R. TGF-β-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 2001;20:2254-72.
51. Lian JB, Shalhoub V, Aslam F, et al. Species-specific glucocorticoid and 1,25-dihydroxyvitamin D responsiveness in mouse MC3T3-E1 osteoblasts: dexamethasone inhibits osteoblast differentiation and vitamin D down-regulates osteocalcin gene expression. Endocrinology 1997;138:2117-27.
52. Ogata Y, Yamauchi M, Kim RH, Li JJ, Freedman LP, Sodek J. Glucocorticoid regulation of bone sialoprotein (BSP) gene expression. Identification of a glucocorticoid response element in the bone sialoprotein gene promoter. Eur J Biochem 1995;230:183-92.
53. Ogata Y, Nakao S, Kim RH, et al. Parathyroid hormone regulation of bone sialoprotein (BSP) gene transcription is mediated through a pituitary-specific transcription factor-1 (Pit-1) motif in the rat BSP gene promoter. Matrix Biol 2000;19:395-407.
54. Shimizu-Sasaki E, Yamazaki M, Furuyama S, Sugiya H, Sodek J, Ogata Y. Identification of a novel response element in the rat bone sialoprotein (BSP) gene promoter that mediates constitutive and fibroblast growth factor 2-induced expression of BSP. J Biol Chem 2001;276:5459-66.
55. Boudreaux JM, Towler DA. Synergistic induction of osteocalcin gene expression: identification of a bipartite element conferring fibroblast growth factor 2 and cyclic AMP responsiveness in the rat osteocalcin promoter. J Biol Chem 1996;271:7508-15.
56. Shimizu-Sasaki E, Yamazaki M, Furuyama S, Sugiya H, Sodek J, Ogata Y. Identification of FGF2-response element in the rat bone sialoprotein gene promoter. Connect Tissue Res 2003;44 Suppl 1:103-8.
57. Pfitzenmaier J, Quinn JE, Odman AM, et al. Characterization of C4-2 prostate cancer bone metastases and their response to castration. J Bone Miner Res 2003;18:1882-8.
58. Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin Cancer Res 2003;9:4505-13.
59. Zayzafoon M, Abdulkadir SA, McDonald JM. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem 2004;279:3662-70.